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Background: Epithelial-mesenchymal transition of tubular cells is a widely recognized mechanism that sustains
interstitial fibrosis in diabetic nephropathy (DN). The signaling of FGF-2, a growth factor involved in this mechanism,
is regulated by glycosaminoglycans. Heparanase-1, an endoglycosidase that cleaves heparan sulfate, is implicated in
the pathogenesis of diabetic nephropathy and is necessary to FGF-2 for the induction of tubular cells transition.
Well known Heparanase-1 inhibitors are heparin(s) and sulodexide, a low-molecular weight heparin – dermatan
sulphate blend, which is effective in the treatment of DN.
Methods: We have investigated the inhibition by sulodexide and its components of Heparanase-1 by an ELISA
assay. We have analyzed its effect on the epithelial-mesenchymal transition of tubular cells by real time gene
expression analysis, zymography and migration assay.
Results: Results show that sulodexide is an effective heparanase-1 inhibitor, exclusively in virtue to the heparin
component, with an IC50 of 5 μg/ml. In FGF-2 treated tubular cells, sulodexide also prevents the over-expression of
the mesenchymal markers αSMA, vimentin and fibronectin and the motility increase, i.e. the epithelial-mesenchymal
transition of tubular cells. Moreover, sulodexide prevents FGF-2 induced heparanase-1 and MMP9 increase
switching off the autocrine loop that FGF-2 activates to support its signal.
Conclusions: The findings highlight the capacity of sulodexide to inhibit heparanase-1 and to control tubular
fibrosis triggered by epithelial-mesenchymal transition. In conclusion, these sulodexide activities support the value
of this agent in controlling the progression of nephropathy to renal failure.
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Diabetic nephropathy (DN) and several other chronic
kidney diseases are characterized by tubular and intersti-
tial fibrosis, which are primarily responsible for acceler-
ating the progression to end-stage renal disease (ESRD)
[1-3]. The epithelial-mesenchymal transition (EMT) of
tubular epithelial cells is a process that sustains these* Correspondence: giovanni.gambaro@rm.unicatt.it
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reproduction in any medium, provided the orevents [4,5], and it is triggered by many factors [6-9]. A
recent work of ours highlighted the central role of FGF-
2 in EMT. Heparanase-1 (HPSE) is needed for EMT and
by regulating syndecan-1 (SDC1) and MMP9 it sustains
the FGF-2 autocrine loop [10]. HPSE is an endo-β-D-
glucuronidase that cleaves heparan sulfate (HS). It takes
part in extracellular matrix (ECM) remodeling and deg-
radation, regulating the release of many HS-bonded
molecules, such as growth factors, chemokines, cyto-
kines, and enzymes, that are involved in inflammation,
wound healing and tumor invasion [11,12]. A body of
literature supports the involvement of HPSE in theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[13-15] and that is why there is great interest in identify-
ing effective HPSE inhibitors capable of controlling
mechanisms of renal damage such as EMT. The best-
characterized HPSE inhibitors are low-molecular-weight
heparin (LMWH) and its derivatives [11]. Previous stud-
ies have shown that sulodexide (a highly purified glyco-
saminoglycan [GAG] isolated from porcine intestinal
mucosa, used since 1974 as an antithrombotic drug) can
control proteinuria and podocyte damage by inhibiting
heparanase [16-18]. Sulodexide consists for 80% of
LMWH and for 20% of dermatan sulfate (DS). The hep-
arin fraction has a molecular weight of 7000 D and a
low degree of sulfation. DS is a polydisperse polysacchar-
ide with an anticoagulant and antithrombotic activity.
The treatment of DN demands additional therapeutic
strategies because strict glycemic control may prove dif-
ficult to achieve in diabetic patients and, even if patients
respond to conventional therapy with ACE inhibitors,
kidney fibrosis slowly continues to progress and eventu-
ally leads to renal failure. It has been demonstrated that
sulodexide and heparin-derived drugs are effective in the
treatment of DN [19,20] and it has recently been sug-
gested that in a rat model of peritoneal dialysis sulodex-
ide prevents EMT in the peritoneal membrane [21]. The
aim of this work was to investigate whether sulodexide
inhibits HPSE, and whether this mechanism can prevent
FGF-2-induced EMT in renal tubular cells. If so, sulo-
dexide would be an interesting agent for controlling




Twenty-five μl of matrigel (Matrigel™ Basement Membrane
Matrix) at a concentration of 200 μg/ml were placed in the
wells of a 96-well plate for ELISA and left to dry under an
extractor hood at room temperature for 90 minutes. Test
samples were prepared by mixing different concentrations
of the GAGs being tested with heparanase (stabilized and
lyophilized HepaOne TM Recombinant Human Hapara-
nase-1 [rhHPA1]- InSight Biopharmaceuticals). The follow-
ing GAGs were tested: sulodexide (Alfa Wassermann), the
LMWH parnaparin (Alfa Wassermann), a commercial der-
matan sulfate (DS) from Sigma (Sigma Aldrich C-3788),
and the LMWH H2046 and dermatan sulfate D2047
(Opocrin). H2046 and D2047 are the two ingredients in
sulodexide, from which they were obtained by affinity
chromatography. The wells containing the matrigel were
washed once with PBT (PBS+ 0.05% Tween 20) before
adding the samples of enzyme/inhibitor, 25 μl per well, in
working buffer (50mM Tris-HCl pH 5; 150 mMNaCl;
0.01% Triton X; protease inhibitor [complete, Roche
Diagnostics]) and incubating overnight at 37°C. Theheparanase enzyme was used at a concentration of 0.5 ng/
μl. Each GAG was tested at four concentrations (5, 10, 20,
50μg/ml). Different GAG mixtures were tested, consisting
of parnaparin with DS, and H2046 with D2047, in propor-
tions of 20:80, 50:50 and 80:20; all GAG mixtures were
tested at the same concentrations. As positive control wells
were incubated overnight in working buffer.
After aspirating the treatment medium and washing
with PBT 200 μl per well, the wells were saturated with
blocking buffer (PBT; 0.5% BSA; 1mM EDTA) and left
for 2 hours under agitation at room temperature. The
blocking buffer was aspirated and the wells were washed
twice with PBT. Then the samples were incubated with
the primary anti-HS antibody (mouse IgM) Clone
HepSS-1 (Seikagaku), 25 μl per well, diluted 1:500 in
blocking buffer, for 1 hour under agitation at room
temperature. Three washing cycles lasting 5 minutes each
with 200 μl of PBT per well were followed by incubation
for 1 hour with the secondary antibody, goat anti-mouse
IgM-HRP (sc-2973, Santa Cruz Biotechnology) 25 μl per
well, diluted 1:1000 in blocking buffer, under agitation at
room temperature. After a further 3 washes lasting 5 min-
utes each with 200 μl per well of PBT, 50 μl of the ABTS
(2.2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) li-
quid substrate system for ELISA (Sigma) was added to
each well and the plate was kept in the dark for 15 min-
utes, then the reaction was blocked with 50 μl per well of
1% SDS (sodium dodecyl sulfate). The absorbance was
read at 405 nm. The percentage of residual HPSE activity
was calculated as follows: (max degradation – OD405
sample)/ max degradation *100.
Where max degradation = OD positive control - OD
0.5 ng/μl of heparanase in working buffer. (the addiction
of GAGs at working buffer do not modify the maximal
HS signal).
Cell cultures
The human renal proximal tubular cell line, HK2
(human kidney 2), was grown in DMEM-F12 (Euro-
Clone) (17.5 mM glucose) supplemented with 10% fetal
bovine serum (Sigma Aldrich), 2 mM L-glutamine, peni-
cillin (100 U/ml) and streptomycin (100 μg/ml), and
maintained at 37°C in a 5% CO2 water-saturated atmos-
phere.
mRNA expression analysis
HK2 cells were grown to subconfluence, starved in
serum-free medium for 24 hours and then cultured in
serum-free medium with 10 ng/ml of FGF-2 (BD Bio-
science) for a further 6 hours, with or without sulodex-
ide (50 μg/ml). Total RNA was extracted from the cells
using the “GenElute Mammalian Total RNA Miniprep”
kit (Sigma Aldrich). The samples were further treated
Figure 1 Reduction of HPSE activity by sulodexide and GAGs.
Histograms showing the percentage of residual heparanase enzyme
activity after incubation with Sulodexide and GAGs at various
concentrations ± SD. All experiments were performed three times in
triplicate.
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tamination. The total amount of RNA and its purity were
checked using the Nanodrop (EuroClone) and 1 μg of
each sample was reverse transcribed into cDNA using
SuperScript II Reverse Transcriptase (Invitrogen) ac-
cording to the manufacturer’s instructions. Real-time PCR
was performed on an ABI-Prism 7500 using Power SYBR
Green Master Mix 2X (Applied Biosystems). A quantita-
tive analysis was performed to assess the expression of
fibronectin fibronectin (FN), vimentin (VIM), matrix-
metalloprotease 9 (MMP9), alpha smooth muscle actin
(αSMA), HPSE, SDC1. Results were normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ex-
pression. The forward and reverse primer sequences have
been reported elsewhere [10]. Gene expression was quan-
tified by means of the comparative Ct method (ΔΔCt) and
the relative quantification (RQ) was calculated as 2-ΔΔCt.
Melting curve analysis was performed to check for any
presence of non-specific amplification products.
Zymography
Gelatin substrate zymography was carried out to assess
the MMP-9 activity in HK2 cell conditioned media using
standard procedures [22]. To obtain the conditioned
media, subconfluent cells were cultured in serum-free
medium for 24 h, then incubated with or without FGF-2
(10 ng/ml) and sulodexide (50 μg/ml) for a further 24 h.
Equal amounts of conditioned media, obtained from the
same number of cells, in sample buffer (4% SDS, 125
mM Tris-HCl pH 6.8, 20% glycerol and 0.05% bromo-
phenol blue) were resolved in non-reducing on 10%
SDS-PAGE gels copolymerized with 0.1% gelatin. After
electrophoresis, the gels were washed twice for 30 min
in 2.5% Triton X-100 at room temperature to remove
SDS, then equilibrated for 30 min in collagenase buffer
(50 mM Tris, 200 mM NaCl, 5 mM CaCl2 and 0.02%
Triton X-100, pH 7.4), and finally incubated overnight
with fresh collagenase buffer at 37°C. Gels were stained
with 0.1% Coumassie Brilliant Blue R-250, 30% MetOH/
10% acetic acid, for 1 hour and destained with 30%
MetOH/10% acetic acid. Digestion bands were analyzed
using the ImageJ software (http://rsb.info.nih.gov/ij/).
Migration assay
We evaluated the migratory ability of cells in the pres-
ence of FGF-2 (10 ng/ml), and with or without sulodex-
ide, parnaparin or DS (50 μg/ml). Briefly, a denuded area
was generated on a quiescent cell monolayer of HK-2
cells by scratching with a sterile pipette tip. The mono-
layer was washed twice with phosphate-buffered saline
(PBS) and then incubated with medium (2% FBS) con-
taining the treatments. The cells were photographed at
different time points. The scratch was measured at three
points in each photo to obtain a mean value. Migrationwas reported as the difference (in mm-1) between the
dimensions of the scratch at the baseline and after 24
hours [23].
Results
Sulodexide inhibits HPSE activity
Our data show that sulodexide 5 μg/ml is capable of
producing a 50% heparanase inhibition; HPSE is inhib-
ited completely with 20 μg/ml of sulodexide (Figure 1A).
Since sulodexide is a mixture of LMWH and dermatan
sulfate, we also analyzed the heparanase inhibiting
effects of two different formulations of LMWH (parna-
parin and H2046) and dermatan sulfates (DS and
D2047). Parnaparin and H2046 completely inhibited
heparanase at a concentration of 5 μg/ml, whereas both
dermatan sulfates proved unable to reduce the enzyme
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μg/ml (Figure 1B).
To see how the relative proportions of heparin and
dermatan sulfate in sulodexide could contribute to its
HPSE inhibitory property, we tested H2046 + D2047,
and parnaparin + DS, both in proportions of 20:80,
50:50 and 80:20. The results showed that both the 80:20
formulations completely abolished HPSE activity at a
concentration of 10 μg/ml (Figure 2 compares the
results for parnaparin + DS versus sulodexide).Sulodexide prevents any increase in mesenchymal marker
expression induced by FGF-2
HK2 renal tubular cells were starved in serum-free
media for 24 hours, then treated for 6 hours with FGF-2
(10 ng/ml) with or without sulodexide (50 μg/ml). Mes-
enchymal marker expression was subsequently measured
by real-time PCR. FGF-2 increased the expression of
alpha αSMA, VIM and FN (all markers of EMT). Sulo-
dexide did not affect the basal levels of αSMA, VIM and
FN, but it completely prevented their FGF-2-induced
overexpression (Figure 3).MMP-9 gene expression and activity
Gene expression analysis showed that sulodexide pre-
vents any increase in FGF-2-induced MMP9 gene ex-
pression without changing its basal expression level
(Figure 4A). Gelatin zymography likewise confirmed that
sulodexide abolished the increase in MMP9 induced by
FGF-2 (Figure 4B).Figure 2 Reduction of HPSE activity by GAG mixtures. Graphs
showing the percentage of residual heparanase enzyme activity after
incubation with sulodexide and parnaparin + DS in proportions of
20:80, 50:50 and 80:20, at concentrations of 5, 10, 20 and 50 μg/ml ±
SD.
Figure 3 Mesenchymal marker expression. A) αSMA, B) VIM and
C) FN gene expression in HK2 cells treated with or without FGF-2
and sulodexide. The results represent the mean ± SD of two
independent experiments performed in triplicate.HPSE and SDC1 regulation
Since we recently demonstrated that FGF-2 increases
HPSE and reduces SDC1 expression, we looked into
whether sulodexide could control these events. We
showed that sulodexide does not affect the basal expres-
sion of HPSE and SDC1 in HK2 cells, but it does
Figure 4 MMP9 expression and activity. A) MMP9 gene
expression in HK2 cells treated with FGF-2 and sulodexide was
measured by real-time PCR. Results represent the mean ± SD of two
independent experiments performed in triplicate. B) Above, a
representative gelatin zymography displaying MMP9 digestion
bands produced by serum-free medium of HK2 cells cultured for 24
hours with FGF-2 and sulodexide. Below, densitometric analysis of
MMP9 digestion bands expressed as a percentage of untreated cells.
Results represent the mean ± SD of three independent experiments
performed in triplicate.
Figure 5 HPSE and SDC1 gene expression. A) HPSE, and B) SDC1
gene expression evaluated by real-time PCR in HK2 cells treated
with or without FGF-2 and sulodexide. Results represent the mean ±
SD of two independent experiments performed in triplicate.
Figure 6 Cell migration. Histograms represent cell migration
(in μm) over 24 hours. Data are the means of three separate
experiments ± SD.
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regulation induced by FGF-2 (Figure 5A and B).
Cell motility
During EMT, renal tubular epithelial cells acquire a
greater motility, making them better able to migrate
through the basal membrane to the interstitium. FGF-2
is one of the factors triggering this event. We showed
that sulodexide significantly reduced the migratory cap-
acity of FGF-2 stimulated cells without influencing basal
cell migration. We also found that parnaparin and
H2046 exhibited the same behavior as sulodexide,
whereas DS and D2047 were unable to inhibit HK2 cell
migration (Figure 6).Discussion
DN occurs in up to 40% of diabetic patients and is one of
the leading causes of ESRD. The approach to treating DN
includes the pursuit of normoglycemia and normotension,
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and treat this complication of diabetes is warranted
because strict metabolic control can be difficult to achieve
in many cases.
The search for new strategies includes seeking molecu-
lar targets and, in this perspective, several studies have
demonstrated the involvement of HPSE in the pathogen-
esis of DN [14], at both tubular and glomerular levels
[24] HPSE could therefore be a pharmacological target
for treating DN. To date, several HPSE inhibitors have
been identified, some of which are now being tested in
clinical trails. Most of them are modified heparins or
LMWHs [25].
GAGs like sulodexide have a favorable effect in DN. A
number of mechanisms have been suggested to explain
the nephroprotective effect of GAGs and sulodexide
[19], including a direct inhibitory effect on HPSE [17],
which reportedly increases in the glomeruli of DN
patients [24]. The chemical composition of sulodexide
gives the product an HPSE inhibiting action [17].
Almost all the above hypothesized mechanisms have
been demonstrated at glomerular level, but one of the
pathological hallmarks of the progression of kidney dis-
ease is tubulo-interstitial fibrosis. The severity of this con-
dition has proved to be much more closely related to the
risk of ESRD than glomerular lesions . The accumulation
of extracellular matrix in the interstitium is sustained by
the transformation of tubular epithelial cells into myofi-
broblasts (EMT) and this event is triggered by several
growth factors and different signaling pathways [5].
We recently showed that HPSE is involved in the
regulation of EMT of tubular cells induced by FGF-2.
HPSE is necessary for FGF-2 to activate the PI3K/AKT
pathway leading to EMT, and for FGF-2 to produce an
autocrine loop by down-regulating SDC1 and up-
regulating MMP9 and the same HPSE [10].
Here we demonstrate that sulodexide – a combination
of GAGs composed of heparin-like (80%) and dermatan
fractions (20%) that is currently used to treat thrombotic
disorders and DN - is an effective HPSE inhibitor cap-
able of preventing FGF-2-induced EMT in renal tubular
cells.
Sulodexide can inhibit HPSE at therapeutic concentra-
tions [26]: its IC50 is 5 μg/ml, and 20 μg/ml of sulodex-
ide suffice to completely inhibit HPSE activity.
Investigating the different power of the two ingredients
in sulodexide, we found H2046 (and parnaparin) a very
effective inhibitor of HPSE, whereas D2047 (and DS)
had only a weak inhibitory action. The results of tests on
combinations containing different proportions of
LMWHs and dermatan sulfates confirmed that sulodex-
ide’s HPSE-inhibiting effect is due exclusively to the hep-
arin component, with no synergistic effect between the
two ingredients.These data are consistent with the results obtained by
Naggi et al [27] using a different experimental approach.
Notably, the Vlodavsky group has shown that sulodexide
had a mild inhibitory effect on heparanase enzymatic ac-
tivity at a concentration of 1 μg/ml, achieving a 50% in-
hibition with 5 μg/ml, and complete inhibition with 50
μg/ml (personal communication).
As expected, sulodexide - being an HPSE inhibitor -
also prevented the overexpression of the mesenchymal
markers αSMA, VIM and FN, i.e. it prevented the
human renal tubular cell EMT induced by FGF-2.
Sulodexide prevented the increase in HPSE and
MMP9 expression and activity and the associated SDC1
reduction that are triggered by FGF-2 in tubular cells,
which means that sulodexide switched off the autocrine
loop that FGF-2 activates to fuel its signal.
The fact that FGF-2 induced cell migration was inhib-
ited by sulodexide and H2046 (and parnaparin), but not
by D2047 (and DS), further confirms that sulodexide
prevents FGF-2-induced EMT through its HPSE inhibit-
ing activity.
Conclusions
In conclusion, the present findings - together with the
recent demonstration that sulodexide prevented any in-
crease in αSMA and decrease in cytokeratin in the peri-
toneal membrane of a rat model of peritoneal dialysis
[21] - support the conviction that sulodexide could pro-
tect against renal fibrosis sustained by EMT, thereby
preventing the progression of chronic kidney disease
(and DN in particular) to ESRD.
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